EUROPEAN HEALTH STAKEHOLDERS NETWORK

Welcome Guest! | Log In
Articles
  • Today, significant advances in basic and clinical medicine have resulted in new clinical options for men living with castration-resistant (hormone-refractory) prostate cancer (CRPC).  Several new classes of treatments have either been approved for use or are under review by the European Medicines Agency. In addition, a number of other agents are in late stages of development promising to...

  • This paper outlines a number of areas that Janssen has identified that, if addressed, might improve the regulatory and market access framework that are associated with the development and availability of drugs in prostate cancer and other diseases.  Janssen has made a number of suggestions as to how improvements might be achieved.

    Issue 1:  Men’s cancers need specific...

  • Four months on from the lively dinner debate on prostate cancer organised by the International Centre for Parliamentary Studies, I would like to put forward my reflections on the points raised. The comments and questions received from the participants related mainly to improved regulatory frameworks and accelerated approval processes and also Health Technology Assessment.

    On the first...

  • Prostate cancer is the most common solid cancer in European men with an incidence of 214 in 100,000 men. About 68,000 men die due to prostate cancer annually. Despite intensified screening measures, still about 15% of men are identified with metastatic PCA at the time of the first diagnosis. Approximately 30% to 50% of patients will develop PSA progression following local therapy with curative...

  • The dramatic growth in scientific research focused prostate cancer continues to challenge health professionals and public health authorities worldwide. Recent publications concerning the efficacy of prostate cancer screening have fuelled public debate concerning appropriate testing policies. Improvements in health care and an aging population in the EU suggest that the management of prostate...